Teacher Retirement System of Texas Purchases 4,076 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Teacher Retirement System of Texas grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 19.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,412 shares of the biotechnology company's stock after purchasing an additional 4,076 shares during the period. Teacher Retirement System of Texas' holdings in Sarepta Therapeutics were worth $3,090,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in SRPT. Wellington Management Group LLP grew its position in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after buying an additional 665,087 shares in the last quarter. Erste Asset Management GmbH bought a new stake in shares of Sarepta Therapeutics during the 3rd quarter valued at about $79,425,000. Janus Henderson Group PLC grew its holdings in shares of Sarepta Therapeutics by 14.2% during the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock worth $544,408,000 after purchasing an additional 543,143 shares in the last quarter. Soros Fund Management LLC purchased a new position in shares of Sarepta Therapeutics during the third quarter worth about $25,800,000. Finally, Swedbank AB bought a new position in shares of Sarepta Therapeutics in the fourth quarter worth approximately $16,706,000. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

SRPT stock traded down $1.40 during trading on Friday, reaching $70.41. The stock had a trading volume of 984,471 shares, compared to its average volume of 1,256,653. The firm has a market cap of $6.83 billion, a PE ratio of 56.33 and a beta of 0.79. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock's 50 day moving average is $102.66 and its two-hundred day moving average is $115.99. Sarepta Therapeutics, Inc. has a 52 week low of $69.81 and a 52 week high of $173.25.

Remove Ads

Wall Street Analyst Weigh In

SRPT has been the subject of a number of research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft cut their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. HC Wainwright reissued a "sell" rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, March 19th. Royal Bank of Canada cut their price objective on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $167.41.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 7.70% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.